Reviewer’s report

Title: Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: Final results from phase II AIO KRK 0105 trial.

Version: 1 Date: 20 August 2013

Reviewer: Angela Marten

Reviewer’s report:

An important trial but due to its one-armed phase II design the discussion and interpretation should be more reluctant. I would delete the reference to the overlapping CI in the conclusion. Moreover, 21% grade 3/4 HFS and 10% grade 3/4 TE one GI perforation are not excellent tolerability to me especially in this population.

Patient selection is not clear to me. As nearly 90% of those who received second-line treatment received FOLFOX/FOLFIRI it remains unclear whether the defined inclusion criteria were chosen well. It would be of interest to provide an overview why the patients qualified for inclusion.

Level of interest: An article of limited interest

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.